Pre-clinical through commercial expertise
Our global network of sites has developed more than 150 mammalian cell culture-based products. We have also brought 4 commercial products to market.
Our mammalian CDMO services are based on standard industry systems for production and manufacturing, including batch, fed-batch and continuous perfusion methods.
We offer a variety of flexible single-use manufacturing scales with options for multiple configurations at our sites in the U.S., Europe, and Japan. We also offer large-scale commercial capabilities using 20,000L stainless steel reactors at our site in Boulder, CO, USA.Got a project? Let's talk.
Years of experience
Commercial mammalian products
Weeks from transfection to clone selection
Extensive experience with numerous cell lines. 150+ mammalian cell-culture based products manufactured.
Pre-clinical to commercial manufacturing using single-use and stainless steel bioreactor technologies with capacities up to 20,000L.
Rapid delivery of monoclonal antibody (mAb) products using our proprietary workflow.
Molecule expertise: monoclonal antibodies (mAbs), coagulation factors, fabs, fusion proteins, antibody-like formats, tri and bispecific antibodies, and more.
Cell types: CHO DG44, CHO GS, CHOK1, HEK293, NS0
Mammalian Production and Manufacturing Services
A proprietary monoclonal antibody (mAb) approach that is robust, scalable and gets you to market faster
Cell line development services, including our CHEF1™ Expression Platform offering seamless process transfer to cGMP manufacturing, shorter timelines, and the ability to meet finite budgets
High-throughput technologies for process development emphasizing characterization, optimization, manufacturability and the robustness of the product yields
6Pack™ single-use bioreactor systems (12,000L) designed for maximum scalability and flexibility and large-scale mammalian manufacturing
Stainless steel bioreactors with 20,000L of manufacturing capacity
In-house quality and regulatory teams ensure your product is ready for any stage, across any regulatory market, anywhere in the world